The Bree Collaborative
Hepatitis C Charter and Roster

Problem Statement

Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. In 2018, an estimated 59,100 Washingtonians were living with HCV, prompting Governor Inslee to issue Directive of the Governor 18-13: “Eliminating Hepatitis C in Washington in 2030 through combined public health efforts and a new medication purchasing approach.”

Aim

To increase evidence-informed screening, monitoring, and access to treatment for Hepatitis C virus (HCV) to reduce the burden of HCV in Washington state.

Purpose

To propose evidence-informed recommendations to the full Bree Collaborative on achieving HCV elimination including:

- Monitoring HCV prevalence and treatment using existing metrics or through new data strategies.
- Improving access to patient-centered preventative and universal screening services for HCV.
- Improving equitable access to HCV treatment and intervention services.
- Building clinical capacity and simplifying clinical workflows to diagnose and treat HCV.
- Identifying engaging, and treating underserved patients with HCV.
- Training and incentivizing primary care providers on how to treat HCV.
- Increasing HCV awareness, education, and reducing stigma.
- Engaging pharmacists as a care team partner.
- Developing reimbursement models to reach patients with HCV outside of traditional delivery systems.

Duties & Functions

The workgroup will:

- Research evidence-informed and expert-opinion informed guidelines and best practices for screening, monitoring, and treating HCV (emerging and established).
- Identify current barriers and future opportunities for implementing interventions.
- Consult relevant professional associations and other stakeholder organizations and subject matter experts for feedback, as appropriate.
- Align with other related state-wide initiatives and Hep C Free Washington.
- Maintain an equity lens while developing recommendations.
- Meet for approximately nine months, as needed.
- Provide updates at Bree Collaborative meetings.
- Post draft report(s) on the Bree Collaborative website for public comment prior to sending report to the Bree Collaborative for approval and adoption.
- Present findings and recommendations in a report.

---

1 US Preventative Services Task Force (2020). Screening for Hepatitis C Virus Infection in Adolescents and Adults. JAMA.
http://www.doh.wa.gov/HepCFreeWA
• Recommend data-driven and practical implementation strategies including metrics or a process for measurement.
• Create and oversee subsequent subgroups to help carry out the work, as needed.
• Revise this charter as necessary based on scope of work.

Structure

The workgroup will consist of individuals confirmed by Bree Collaborative members or appointed by the chair of the Bree Collaborative. The Bree Collaborative director and program coordinator will staff and provide management and support services for the workgroup.

Less than the full workgroup may convene to: gather and discuss information; conduct research; analyze relevant issues and facts; or draft recommendations for the deliberation of the full workgroup. A quorum shall be a simple majority and shall be required to accept and approve recommendations to send to the Bree Collaborative.

Meetings

The workgroup will hold meetings as necessary. Bree Collaborative staff will conduct meetings, arrange for the recording of each meeting, and distribute meeting agendas and other materials prior to each meeting. Additional workgroup members may be added at the discretion of the Bree Collaborative director.

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abha Puri, MPH</td>
<td>Program Manager</td>
<td>Community Health Plan of Washington</td>
</tr>
<tr>
<td>Emalie Huriaux, MPH</td>
<td>STD, Adult Hepatitis, and Syringe Service Program (SSP) Manager</td>
<td>Washington State Department of Health</td>
</tr>
<tr>
<td>John Scott, MD, MSc</td>
<td>Professor, Department of Medicine Medical Director, Telehealth</td>
<td>University of Washington</td>
</tr>
<tr>
<td></td>
<td>Associate Medical Director, Liver Clinic</td>
<td></td>
</tr>
<tr>
<td>Jon Stockton, MHA</td>
<td>Adult Viral Hepatitis Coordinator</td>
<td>Washington State Department of Health</td>
</tr>
<tr>
<td>Judith Tsui, MD, MPH</td>
<td>Associate Professor, Department of Medicine Director, UW Medical Student Addiction Research Program</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Melda Velasquez</td>
<td>Service Line Director</td>
<td>Kadlec Regional Medical Center</td>
</tr>
<tr>
<td>Omar Daoud, PharmD</td>
<td>Director of Pharmacy</td>
<td>Community Health Plan of Washington</td>
</tr>
<tr>
<td>Patrick Judkins</td>
<td>Education and Outreach Specialist, Disease Control and Prevention</td>
<td>Thurston County Health Department</td>
</tr>
<tr>
<td>Ryan Pistoresi, PharmD, MS</td>
<td>Assistant Chief Pharmacy Officer</td>
<td>WA Health Care Authority</td>
</tr>
<tr>
<td>Wedny Wong, BSc</td>
<td>Ambulatory Clinical Pharmacist</td>
<td>Providence Health and Services</td>
</tr>
<tr>
<td>Vania Rudolph, MD, MPH</td>
<td>Addiction Medicine Specialist</td>
<td>Swedish Health Centers</td>
</tr>
<tr>
<td>Yumi Ando, MD</td>
<td>Gastroenterology Specialist</td>
<td>Kaiser Permanente</td>
</tr>
</tbody>
</table>